HC Wainwright Has Strong Forecast for TSE:GLX Q3 Earnings

Bradmer Pharmaceuticals Inc. (TSE:GLX) – Research analysts at HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for shares of Bradmer Pharmaceuticals in a report issued on Wednesday, August 6th. HC Wainwright analyst M. Colonnese now expects that the company will post earnings of ($0.03) per share for the quarter, up from their previous estimate of ($0.10). HC Wainwright also issued estimates for Bradmer Pharmaceuticals’ Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.39) EPS, Q1 2026 earnings at ($0.41) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($1.49) EPS.

GLX has been the topic of several other research reports. Rosenblatt Securities upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, June 24th. Maxim Group upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 31st. The Goldman Sachs Group upgraded Bradmer Pharmaceuticals to a “hold” rating in a report on Thursday, July 31st. Finally, BTIG Research upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, April 14th. One equities research analyst has rated the stock with a hold rating and six have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Strong Buy”.

Bradmer Pharmaceuticals Stock Performance